Table 1.
No. | Age (months) | Sex | tTG Ig A (U/ml) | EMA | AGA IgA (U/ml) | AGA IgG (U/ml) | Risk factor and clinical presentation | CD diagnosis |
---|---|---|---|---|---|---|---|---|
1 | 27 | F | >200.0 | + | 15.0 | 127.0 | Inappetence | MDB + |
2 | 67 | M | 40.7 | + | 8.0 | 18.9 | None | MDB + |
3 | 41 | M | 35.0 | + | 9.3 | 41.0 | CD in the sister | MDB + |
4 | 44 | M | 102.0 | + | 1.4 | 1.1 | None | MDB + |
5 | 24 | F | 11.6 | - | 0.2 | 6.4 | Diarrhea | MDB + |
6 | 60 | M | >200 | + | 93.0 | 85.5 | None | HLA + |
7 | 44 | F | 3.6 | +/- | 1.2 | 17.0 | Growth failure | DH |
8 | 20 | M | 23.0 | + | 1.4 | 9.0 | None | n.p. |
9 | 44 | M | 15.0 | + | 1.6 | 9.6 | None | n.p. |
10a | 58 | F | n.a. | n.a. | n.a. | n.a. | Growth failure Dental enamel defects | MDB +, HLA + |
M male, F female, tTG Ig A anti-transglutaminase antibodies, EMA anti-endomysium antibodies, AGA IgA and IgG: anti-gliadin antibodies; cut -off values for tTG IgA, AGA IgA and AGA IgG: positive: > 10U/ml; borderline: 7–10 U/ml, negative: <7 U/ml; EMA: “+”: positive result; “-“: negative result; “+/-“: doubt result; n.p. not performed, n.a. not available, HLA+ human leukocyte antigen positivity, MDB + multiple duodenal biopsies positivitym, DH Duhring Dermatitis Herpetiformis
aASD patient who had received a CD diagnosis before the hospitalization in our ASD Unit and for which serological data are not available